Novo Nordisk dips after latest trial on its new weight-loss drug disappoints
Novo Nordisk shares fell after the results for the latest trial of its next-generation weight-loss shot, CagriSema, disappointed investors as the race for the next miracle weight-loss drug heats up.
CagriSema helped patients lose 15.7% of their weight over 68 weeks, compared to 3.1% with a placebo, Novo Nordisk reported. In an earlier trial, patients lost 22.7% of their body weight in the same time span.
Patients on Novo Nordisk’s blockbuster weight-loss drugs Ozempic and Wegovy lose about 15% of their body weight in 68 weeks. If the latest trial on CagriSema holds up, it would be just as effective as the drugs Novo Nordisk already sells.
The Danish pharmaceutical giant is looking to develop a successor drug, especially considering that Eli Lilly’s weight-loss drugs (which entered the market later) appear to be more more effective than Novo Nordisk’s. Amgen is also looking to enter the weight-loss drug arena with its new drug MariTide, which has shown promising results in its trials thus far.
Patients on Novo Nordisk’s blockbuster weight-loss drugs Ozempic and Wegovy lose about 15% of their body weight in 68 weeks. If the latest trial on CagriSema holds up, it would be just as effective as the drugs Novo Nordisk already sells.
The Danish pharmaceutical giant is looking to develop a successor drug, especially considering that Eli Lilly’s weight-loss drugs (which entered the market later) appear to be more more effective than Novo Nordisk’s. Amgen is also looking to enter the weight-loss drug arena with its new drug MariTide, which has shown promising results in its trials thus far.
